Circadian Phase Assessments at Home
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
An estimated 23 million Americans, including adolescents and the elderly, suffer from circadian rhythm sleep disorders, such as delayed sleep phase disorder, advanced sleep phase disorder and winter depression. These conditions are characterized by persistent insomnia and/or excessive daytime sleepiness, impaired performance, reduced well being and lower quality of life. The negative symptoms result from a misalignment between the timing of sleep and the internal circadian clock. Clinical research has demonstrated that circadian rhythm sleep disorders are most effectively diagnosed (differentiated from other causes of insomnia) and treated if each individual patient's circadian phase is known. The timing of the master internal circadian clock is most reliably measured from the onset of the endogenous circadian rhythm of melatonin, a neuroendocrine hormone, as measured in dim light (dim light melatonin onset, or "DLMO"). However to date the reliable and valid assessment of the DLMO is limited to the research laboratory setting.
This study is to test a streamlined procedure for the accurate assessment of circadian phase (DLMO) outside of the laboratory that will provide clinicians and researchers with a novel diagnostic and research tool. In this way the underlying neurobiological cause of a patient's insomnia and/or circadian rhythm disorder can more readily be diagnosed and treated.
Specific Aim 1 is to validate procedures for at-home circadian phase assessment in a sample of healthy people. Validation will occur by (1) objectively measuring compliance to the at-home procedures and (2) comparing DLMOs collected at home to DLMOs collected in the laboratory, in a within-subjects counterbalanced design. Specific Aim 2 is to validate the same at home procedures in patients with delayed sleep phase disorder. Specific Aim 3 is to conduct rigorous analyses to inform future users which subject characteristics and light levels predict (1) compliance to the at home procedures and (2) valid at-home DLMOs.
The results of this 3 year study will have substantial implications for the translation of basic and clinical research to the community: (1) the diagnosis and treatment of insomnia and circadian rhythm sleep disorders will be significantly enhanced, thus improving public health and safety, mood and quality of life, (2) community participation in research will be improved, particularly in vulnerable and under represented populations, thus increasing scientific knowledge and (3) research and clinical costs will be substantially reduced.
| Condition | Intervention | Phase |
|---|---|---|
|
Healthy Controls Delayed Sleep Phase Disorder. |
Behavioral: At home saliva sampling |
Phase 0 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Outcomes Assessor) Primary Purpose: Diagnostic |
- Dim Light Melatonin Onset [ Time Frame: 9 days ] [ Designated as safety issue: No ]The DLMO is assessed twice at home and twice in the laboratory.
| Estimated Enrollment: | 68 |
| Study Start Date: | December 2011 |
| Estimated Study Completion Date: | March 2014 |
| Estimated Primary Completion Date: | March 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Healthy Controls |
Behavioral: At home saliva sampling
Saliva samples taken every half an hour in evening before bedtime.
|
| Active Comparator: Delayed Sleep Phase Disorder |
Behavioral: At home saliva sampling
Saliva samples taken every half an hour in evening before bedtime.
|
Eligibility| Ages Eligible for Study: | 18 Years to 69 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy adult volunteers or people with Delayed Sleep Phase Disorder
Exclusion Criteria:
- Color blindness with the Ishihara test
Contacts and Locations| Contact: Helen Burgess, PhD | Helen_J_Burgess@rush.edu |
| United States, Illinois | |
| Rush University Medical Center | Recruiting |
| Chicago, Illinois, United States, 60612 | |
More Information
No publications provided
| Responsible Party: | Helen Burgess, Associate Professor, Rush University Medical Center |
| ClinicalTrials.gov Identifier: | NCT01487252 History of Changes |
| Other Study ID Numbers: | AT007104 |
| Study First Received: | December 2, 2011 |
| Last Updated: | August 16, 2012 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Sleep Disorders, Circadian Rhythm Chronobiology Disorders Nervous System Diseases Dyssomnias |
Sleep Disorders Occupational Diseases Mental Disorders |
ClinicalTrials.gov processed this record on May 21, 2013